Search Result

Pathways Recommended:	PI3K/Akt/mTOR

Results for "

MTOR complex

" in MedChemExpress (MCE) Product Catalog:

By Targets:	mTOR (29) Aminoacyl-tRNA Synthetase (1) AMPK (6) Apoptosis (14) Autophagy (20) Bacterial (3) CDK (1) DNA/RNA Synthesis (3) ERK (1) FKBP (4) HSP (1) IFNAR (2) Influenza Virus (3) Isotope-Labeled Compounds (4) Mitochondrial Metabolism (5) Oxidative Phosphorylation (1) PI3K (3) Ras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (7) RIP kinase (1) SARS-CoV (2) Sirtuin (1) ULK (1)
By Research Areas:	Cancer (34) Infection (5) Inflammation/Immunology (4) Metabolic Disease (8) Neurological Disease (7)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: mTOR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13003

Torin 1 Maximum Cited Publications 125 Publications Verification	mTOR Autophagy	Cancer
Torin 1 is a potent inhibitor of *mTOR* with an IC₅₀ of 3 nM. Torin 1 inhibits both mTORC1/2 complexes with IC₅₀ values between 2 and 10 nM. Torin 1 is an effective inducer of autophagy.

HY-10218

Everolimus 110+ Cited Publications RAD001; SDZ-RAD	mTOR FKBP Autophagy Apoptosis Bacterial	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective, orally active, blood-brain barrier-permeable *mTOR1* inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-N0112

Dihydromyricetin 20+ Cited Publications Ampelopsin; Ampeloptin	mTOR Influenza Virus DNA/RNA Synthesis Autophagy	Infection Cancer
Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting *mTOR* signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

HY-10681

Gedatolisib 5 Publications Verification PKI-587; PF-05212384	PI3K mTOR	Cancer
Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and *mTOR* with IC₅₀s of 0.4 nM, 5.4 nM and 1.6 nM, respectively . Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2 .

HY-15247

Vistusertib 30+ Cited Publications AZD2014	mTOR Autophagy Apoptosis	Cancer
Vistusertib (AZD2014) is an ATP competitive *mTOR* inhibitor with an IC₅₀ of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes.

HY-16397A

Phenformin hydrochloride 5+ Cited Publications Phenethylbiguanide hydrochloride	Apoptosis mTOR Autophagy Mitochondrial Metabolism AMPK	Neurological Disease Metabolic Disease Cancer
Phenformin (Phenethylbiguanide) hydrochloride is an orally active biguanide hypoglycemic agent. Phenformin hydrochloride inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the *mTOR* pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin hydrochloride inhibits cancer stem cells (CSCs) and possesses potent antitumor potential .

HY-16397

Phenformin 5+ Cited Publications Phenethylbiguanide	Mitochondrial Metabolism AMPK Apoptosis Autophagy mTOR	Neurological Disease Metabolic Disease Cancer
Phenformin (Phenethylbiguanide) is an orally active biguanide hypoglycemic agent. Phenformin inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the *mTOR* pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin inhibits cancer stem cells (CSCs) and possesses potent antitumor potential .

HY-134508

C24-Ceramide	mTOR	Neurological Disease Cancer
C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer .

HY-50710

KU-0063794 10+ Cited Publications	mTOR	Cancer
KU-0063794 is a potent and specific *mTOR* inhibitor, inhibiting both the mTORC1 and mTORC2 complexes with IC₅₀s of 10 nM.

HY-137978A

Ezurpimtrostat hydrochloride 3 Publications Verification GNS561 hydrochloride	SARS-CoV IFNAR Autophagy Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Ezurpimtrostat hydrochloride (GNS561 hydrochloride) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat hydrochloride inhibits PPT1, dysregulates lysosomal function, redistributes *mTOR, and induces apoptosis. Ezurpimtrostat hydrochloride reduces IFN‑α, CRP, immune complex* deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat hydrochloride can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .

HY-175751

LRK-4189	mTOR	Cancer
LRK-4189 is an orally active PIP4K2C (a regulator of *mTOR* complex) degrader and type 1 immune activator. LRK-4189 induces the degradation of the lipid kinase PIP4K2C. LRK-4189 triggers the interferon signaling pathway in microsatellite-stable (MSS) colorectal cancer cells, activates immunogenic tumor killing, and induces endogenous cell death. LRK-4189 sensitizes microsatellite-stable colorectal cancer tumors to NK cell killing and dendritic cell phagocytosis. LRK-4189 can be used for the research of microsatellite-stable colorectal cancer .

HY-100222

CZ415 4 Publications Verification	mTOR	Cancer
CZ415 is a potent and highly selective *mTOR* inhibitor with a pIC₅₀ of 8.07. CZ415 inhibits mTORC1 and mTORC2 protein complex.

HY-15248

GDC-0349 2 Publications Verification	mTOR Autophagy	Cancer
GDC-0349 is a potent and selective ATP-competitive *mTOR* inhibitor with a K_i of 3.8 nM. GDC-0349 inhibits of both mTORC1 and mTORC2 complexes.

HY-10218S

Everolimus-d4 RAD001-d₄; SDZ-RAD-d₄	mTOR FKBP Autophagy Apoptosis	Cancer
Everolimus-d₄ is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-136265

BC-LI-0186 1 Publications Verification	Aminoacyl-tRNA Synthetase	Cancer
BC-LI-0186 is a potent and selective inhibitor of Leucyl-tRNA synthetase (LRS; LeuRS) and Ras-related GTP-binding protein D (RagD) interaction (IC₅₀=46.11 nM). BC-LI-0186 competitively binds to the RagD interacting site of LRS (K_d=42.1 nM) and has on effects on LRS-Vps34, LRS-EPRS, RagB-RagD association, mTORC1 complex formation or the activities of 12 kinases. BC-LI-0186 can effectively suppress the activity of cancer-associated?MTOR?mutants and the growth of rapamycin-resistant cancer cells.?BC-LI-0186 is a promising agent for lung cancer research .

HY-15272

WAY-600 5+ Cited Publications	mTOR	Inflammation/Immunology Cancer
WAY-600 is a potent, ATP-competitive, and selective *mTOR* inhibitor with an IC₅₀ of 9 nM for recombinant mTOR enzyme. WAY-600 blocks mTOR complex 1/2 (mTORC1/2) assemble and activation.

HY-10218R

Everolimus (Standard) RAD001 (Standard); SDZ-RAD (Standard)	Reference Standards mTOR FKBP Autophagy Apoptosis Bacterial	Cancer
Everolimus (Standard) is the analytical standard of Everolimus. This product is intended for research and analytical applications. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active *mTOR1* inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-137978

Ezurpimtrostat 3 Publications Verification GNS561	SARS-CoV IFNAR Autophagy Apoptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
Ezurpimtrostat (GNS561) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat inhibits PPT1, dysregulates lysosomal function, redistributes *mTOR, and induces apoptosis. Ezurpimtrostat reduces IFN‑α, CRP, immune complex* deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .

HY-10681R

Gedatolisib (Standard)	PI3K mTOR Reference Standards	Cancer
Gedatolisib (Standard) is the analytical standard of Gedatolisib. This product is intended for research and analytical applications. Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively . Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2 .

HY-W348485

WRX606	mTOR	Cancer
WRX606 is an orally active nonrapalog inhibitor for mTOR complex 1 (mTORC1M). WRX606 inhibits the phosphorylation of mTORC1 substrate S6 kinase 1 (S6K1) (IC₅₀ = 10 nM) and eukaryotic translation initiation factor 4E binding protein (p-4E-BP1) (IC₅₀ = 0.27 μM) in MCF-7 cells. WRX606 suppresses tumor growth in mice without promotion of metastasis. WRX606 can be studied in research as an antitumor agent .

HY-161509

PT-88	mTOR	Cancer
PT-88 is a highly selective inhibitor of mTOR (Mammalian target of rapamycin) (IC₅₀=1.2 nM). PT-88 inhibits both mTORC1 and mTORC2 complexes, both of which are active forms of mTOR protein kinases and are closely associated with cell growth, proliferation, and survival. PT-88 can be used to study the role of mTOR in tumorigenesis and development, especially in the study of breast cancer .

HY-15247R

Vistusertib (Standard) AZD2014 (Standard)	mTOR Autophagy Apoptosis Reference Standards	Cancer
Vistusertib (Standard) is the analytical standard of Vistusertib. This product is intended for research and analytical applications. Vistusertib (AZD2014) is an ATP competitive mTOR inhibitor with an IC50 of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes.

HY-136479

F0911-7667	Sirtuin	Cancer
F0911-7667 is a SIRT1 activator that induces autophagic cell death in U87MG and T98G cells by activating the AMPK-mTOR-ULK complex. CWR tripeptide was also identified as a SIRT1 activator that reduced p53 acetylation in IMR32 neuroblastoma cells and protected cells from cell death induced by Aβ fragments .

HY-124582

NEO214 1 Publications Verification	Autophagy mTOR	Cancer
NEO214 is an autophagy inhibitor and a covalent conjugate of the PDE4 inhibitor Rolipram (HY-16900) and perillyl alcohol (HY-N7000). It has anti-cancer activity and blood-brain barrier (BBB) permeability. Over sex. NEO214 prevents autophagy-lysosome fusion, thereby blocking autophagic flux and triggering glioma cell death. The process involves mTOR activation, andTFEB(Transcription Factor EB) aggregation. NEO214 inhibitionMacroautophagy/autophagy in glioblastoma cells has the potential to overcome chemotherapy resistance in glioblastoma .

HY-115507

NMac1	AMPK mTOR ERK Oxidative Phosphorylation Reactive Oxygen Species (ROS) Ras	Cancer
NMac1 is an orally active Nm23/NDPK activator. NMac1 directly binds to Nm23-H1 and activates the NDPK activity of recombinant Nm23-H1 with an EC₅₀ of 10.7 uM. NMac1 induces AMPK activation and inhibits *mTOR* and ERK, leading to mitochondrial OXPHOS dysregulation and suppressing mitochondrial ROS production, which in turn induces mitochondrial dysfunction in MDA-MB-231 cells. NMac1 inhibits Complex I activity and suppresses changes in morphology and actin cytoskeleton organization following Rac1 activation in MDA-MB-231 cells. NMac1 inhibits tumor invasion, migration and metastasis. NMac1 is useful for studying metastatic tumors, such as breast cancer. NMac1 can be isolated from the ginger cassumunar Roxb .

HY-N0112R

Dihydromyricetin (Standard) Ampelopsin (Standard); Ampeloptin (Standard)	Reference Standards mTOR Influenza Virus DNA/RNA Synthesis Autophagy	Infection Cancer
Dihydromyricetin (Standard) is the analytical standard of Dihydromyricetin. This product is intended for research and analytical applications. Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting mTOR signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

HY-10218S1

Everolimus-13C2,d4 RAD001-¹³C₂,d₄; SDZ-RAD-¹³C₂,d₄	Isotope-Labeled Compounds Bacterial Autophagy FKBP mTOR Apoptosis	Cancer
Everolimus- ¹³C₂,d₄ (RAD001- ¹³C₂,d₄) is ¹³C labeled Everolimus. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active *mTOR1* inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-N0112S

Dihydromyricetin-d4 Ampelopsin-d₄; Ampeloptin-d₄	Isotope-Labeled Compounds Autophagy Influenza Virus mTOR DNA/RNA Synthesis	Infection Cancer
Dihydromyricetin-d₄ (Ampelopsin-d₄) is deuterium labeled Dihydromyricetin. Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting *mTOR* signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

HY-16397AS

Phenformin-d5 hydrochloride Phenethylbiguanide-d₅ hydrochloride	Isotope-Labeled Compounds Apoptosis mTOR Autophagy Mitochondrial Metabolism AMPK	Neurological Disease Metabolic Disease Cancer
Phenformin-d₅ (Phenethylbiguanide-d₅) hydrochloride is the deuterium labeled Phenformin hydrochloride. Phenformin hydrochloride is an orally active biguanide hypoglycemic agent. Phenformin hydrochloride inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the *mTOR* pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin hydrochloride inhibits cancer stem cells (CSCs) and possesses potent antitumor potential.

HY-16397AR

Phenformin hydrochloride (Standard) Phenethylbiguanide hydrochloride (Standard)	Reference Standards Apoptosis mTOR Autophagy Mitochondrial Metabolism AMPK	Neurological Disease Metabolic Disease Cancer
Phenformin (Phenethylbiguanide) hydrochloride (Standard) is the analytical standard of Phenformin hydrochloride (HY-16397). This product is intended for research and analytical applications. Phenformin hydrochloride (Phenethylbiguanide) is an orally active biguanide hypoglycemic agent. Phenformin hydrochloride inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the *mTOR* pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin hydrochloride inhibits cancer stem cells (CSCs) and possesses potent antitumor potential.

HY-16397R

Phenformin (Standard) Phenethylbiguanide (Standard)	Reference Standards Apoptosis mTOR Autophagy Mitochondrial Metabolism AMPK	Neurological Disease Metabolic Disease Cancer
Phenformin (Phenethylbiguanide) (Standard) is the analytical standard of Phenformin (HY-16397). This product is intended for research and analytical applications. Phenformin (Phenethylbiguanide) is an orally active biguanide hypoglycemic agent. Phenformin inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the *mTOR* pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin inhibits cancer stem cells (CSCs) and possesses potent antitumor potential.

HY-10681S

Gedatolisib-d8 PKI-587-d₈; PF-05212384-d₈	Isotope-Labeled Compounds PI3K mTOR	Cancer
Gedatolisib-d₈ (PKI-587-d₈) is the deuterium labeled Gedatolisib (HY-10681). Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC₅₀s of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2 .

HY-100222R

CZ415 (Standard)	mTOR Reference Standards	Cancer
CZ415 (Standard) is the analytical standard of CZ415 (HY-100222). This product is intended for research and analytical applications. CZ415 is a potent and highly selective mTOR inhibitor with a pIC50 of 8.07. CZ415 inhibits mTORC1 and mTORC2 protein complex.

HY-181062

VWK147	HSP Apoptosis Autophagy ULK RIP kinase CDK	Cancer
VWK147 is a second-generation HSP90 C-terminal domain (CTD) inhibitor. VWK147 targets the CTD dimerization interface, prevents HSP90 CTD dimerization, disrupts co-chaperone PPID binding to HSP90 CTD, and inhibits HSP90 chaperone function dependent on dimerization. VWK147 reduces protein levels of HSP90 client proteins ULK1, RIPK1, and CDK4 without inducing a heat shock response. VWK147 induces cell death, including apoptosis, in Cisplatin (HY-17394)-sensitive and -resistant urothelial carcinoma cells. VWK147 induces LC3-II accumulation, inhibits autophagosome-lysosome fusion to block canonical autophagy, and induces non-canonical LC3 lipidation independent of ULK1 and PIK3C3 complexes. VWK147 can be used for the research of urothelial carcinoma .

Cat. No.	Product Name

HY-L034

Anti-Aging Compound Library	7,297 compounds
Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. MCE Anti-Aging Compound Library contains 7,297 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

Anti-Aging Compound Library

7,297 compounds

Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.

MCE Anti-Aging Compound Library contains 7,297 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

Cat. No.	Product Name	Type

HY-134508

C24-Ceramide	Biochemical Assay Reagents
C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer .

C24-Ceramide

Biochemical Assay Reagents

C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0112

Dihydromyricetin 20+ Cited Publications Ampelopsin; Ampeloptin	Infection Flavanonols Structural Classification Flavonoids other families Classification of Application Fields Phenols Polyphenols Plants Disease Research Fields Source Classification	mTOR Influenza Virus DNA/RNA Synthesis Autophagy
Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting *mTOR* signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

HY-N0112R

Dihydromyricetin (Standard) Ampelopsin (Standard); Ampeloptin (Standard)	Flavanonols Structural Classification Flavonoids other families Phenols Polyphenols Plants Source Classification	Reference Standards mTOR Influenza Virus DNA/RNA Synthesis Autophagy
Dihydromyricetin (Standard) is the analytical standard of Dihydromyricetin. This product is intended for research and analytical applications. Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting mTOR signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

Species:	Human (2)
Tag:	His (2)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P71583

	LAMTOR1 Protein, Human (His) C11orf59; LAMTOR1; Late endosomal/lysosomal adaptor and MAPK and MTOR activator 1; Lipid raft adaptor protein p18; LTOR1_HUMAN; p18; p27Kip1-releasing factor from RhoA; p27RF-Rho; PDRO; PP7157; Protein associated with DRMs and endosomes; Ragulator complex protein LAMTOR1; ragulator complex protein PDRO; Ragulator1; RhoA activator C11orf59	Human	E. coli
	The LAMTOR1 protein is an important component of the Ragulator complex and plays dual roles in amino acid sensing and mTORC1 activation. It acts as a guanine nucleotide exchange factor (GEF) for Rag GTPases and mediates their recruitment to the lysosomal membrane. LAMTOR1 Protein, Human (His) is the recombinant human-derived LAMTOR1 protein, expressed by E. coli , with N-His labeled tag.

HY-P70931

	MAPKSP1 Protein, Human (His) Ragulator complex Protein LAMTOR3; Late Endosomal/Lysosomal Adaptor and MAPK and MTOR Activator 3; MEK-Binding Partner 1; Mp1; Mitogen-Activated Protein Kinase Kinase 1-Interacting Protein 1; Mitogen-Activated Protein Kinase Scaffold Protein 1; LAMTOR3; MAP2K1IP	Human	E. coli
	The MAPKSP1 protein, also known as porphobilinogen deaminase (HMBS), is crucial in the heme biosynthetic pathway and catalyzes the sequential polymerization of four porphobilinogen molecules to form hydroxymethyl bixane. The process begins with the assembly of the dipyrromethane cofactor of porphobilinogen or preuroporphyrinogen. MAPKSP1 Protein, Human (His) is the recombinant human-derived MAPKSP1 protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10218S

Everolimus-d4
Everolimus-d₄ is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-10218S1

Everolimus-13C2,d4

Everolimus- ¹³C₂,d₄ (RAD001- ¹³C₂,d₄) is ¹³C labeled Everolimus. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-N0112S

Dihydromyricetin-d4

Dihydromyricetin-d₄ (Ampelopsin-d₄) is deuterium labeled Dihydromyricetin. Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting mTOR signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

HY-16397AS

Phenformin-d5 hydrochloride

Phenformin-d₅ (Phenethylbiguanide-d₅) hydrochloride is the deuterium labeled Phenformin hydrochloride. Phenformin hydrochloride is an orally active biguanide hypoglycemic agent. Phenformin hydrochloride inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the mTOR pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin hydrochloride inhibits cancer stem cells (CSCs) and possesses potent antitumor potential.

HY-10681S

Gedatolisib-d8
Gedatolisib-d₈ (PKI-587-d₈) is the deuterium labeled Gedatolisib (HY-10681). Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC₅₀s of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2 .

Host:	Rabbit (6)
Reactivity:	Human (6) Rat (4) Mouse (6)
Application:	IHC-P (5) ICC/IF (3) IP (3) WB (6) FC (1) ELISA (2)
Isotype:	IgG (6)
Conjugation:	Non-conjugated (6)
Clonality:	Polyclonal (2) Monoclonal (3) Recombinant (1)
Modification:	Phosphorylated (3) Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80759

	mTOR Antibody 1 Publications Verification MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase MTOR; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; Mammalian target of rapamycin; MTOR; Mechanistic tar	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	mTOR Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to mTOR.

HY-P80838

	Phospho-mTOR (Ser2481) Antibody MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase MTOR; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; Mammalian target of rapamycin; MTOR; Mechanistic tar	WB	Human, Mouse, Rat
	Phospho-mTOR (Ser2481) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-mTOR (Ser2481).

HY-P86389

	mTOR Antibody (YA6081) MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase MTOR; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; Mammalian target of rapamycin; MTOR; Mechanistic tar	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	mTOR Antibody (YA6081) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to mTOR.

HY-P80837

	Phospho-mTOR (Ser2448) Antibody (YA171) 2 Publications Verification MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase MTOR; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; Mammalian target of rapamycin; MTOR; Mechanistic tar	WB, IHC-P	Human, Mouse
	Phospho-mTOR (Ser2448) Antibody (YA171) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-mTOR (Ser2448).

HY-P86383

	Phospho-mTOR(Ser2448) Antibody (YA6075) MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase MTOR; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; Mammalian target of rapamycin; MTOR; Mechanistic tar	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Phospho-mTOR(Ser2448) Antibody (YA6075) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-mTOR(Ser2448).

HY-P80837A

	Phospho-mTOR (Ser2448) Antibody (YA171)(PBS only) MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase MTOR; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; Mammalian target of rapamycin; MTOR; Mechanistic tar	WB, IHC-P	Human, Mouse
	Phospho-mTOR (Ser2448) Antibody (YA171) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-mTOR (Ser2448).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-134508

C24-Ceramide		Phospholipids
C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MTOR complex

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products